Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Glaukos Trading Down 1.0 %
Shares of NYSE:GKOS traded down $0.52 on Friday, hitting $52.98. 635,685 shares of the company's stock were exchanged, compared to its average volume of 507,366. Glaukos has a 12 month low of $33.33 and a 12 month high of $64.49. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -44.52 and a beta of 1.41. The business's 50 day simple moving average is $47.24 and its two-hundred day simple moving average is $50.28. The company has a debt-to-equity ratio of 0.63, a current ratio of 6.78 and a quick ratio of 8.39.
Glaukos (NYSE:GKOS - Get Rating) last released its earnings results on Wednesday, May 4th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.14. Glaukos had a negative return on equity of 13.82% and a negative net margin of 19.35%. The business had revenue of $67.70 million during the quarter, compared to the consensus estimate of $60.85 million. During the same period last year, the company earned ($0.21) earnings per share. The business's revenue for the quarter was down .4% compared to the same quarter last year. Analysts anticipate that Glaukos will post -2.03 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on GKOS shares. Citigroup lifted their price objective on shares of Glaukos from $49.00 to $54.00 in a research note on Thursday. Stifel Nicolaus raised shares of Glaukos from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $40.00 to $60.00 in a research note on Tuesday, July 12th. Finally, BTIG Research lifted their price objective on shares of Glaukos from $61.00 to $66.00 in a research note on Monday, April 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $57.38.